Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CDC7 | O00311 | 10/20 | 0.51 |
| ▸ | CDK2 | P24941 | 9/20 | 0.51 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.51 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12821400 | 0.84 | ROCK1 (1.00) | ROCK1MAPTCDC7CDK2MAP3K14 | |
| SCHEMBL1613026 | 0.79 | CDC7 (0.70) | ROCK1CDC7CDK2MAP3K14RPS6KA5 | |
| SCHEMBL28554877 | 0.78 | ROCK1 (0.57) | ROCK1MAPTCDC7CDK2MAP3K14 | |
| SCHEMBL30459869 | 0.77 | FGFR1 (0.56) | ROCK1MAPTMAP3K14RPS6KA5 | |
| SCHEMBL20548870 | 0.77 | RPS6KA5 (0.50) | ROCK1MAPTRPS6KA5MAOBHTR2A | |
| SCHEMBL17683156 | 0.77 | FGFR1 (0.56) | ROCK1MAPTMAP3K14RPS6KA5 | |
| SCHEMBL35210329 | 0.77 | RPS6KA5 (0.50) | ROCK1MAPTRPS6KA5MAOBHTR2A | |
| SCHEMBL28568052 | 0.76 | ROCK1 (0.60) | ROCK1MAPTCDC7RPS6KA5MAOB | |
| SCHEMBL5659028 | 0.75 | RPS6KA5 (0.68) | ROCK1MAPTCDC7CDK2MAP3K14 | |
| SCHEMBL30459871 | 0.75 | RPS6KA5 (0.68) | ROCK1MAPTCDC7CDK2MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398939-B1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3398939-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | ROCK1 1838/4885MAPT 1913/4885CDC7 1594/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | ROCK1 1838/4885MAPT 1913/4885CDC7 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.